The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The median overall survival was 32 months in patients who received adjuvant chemotherapy and 26 months in patients who did not. Adjuvant multi-agent chemotherapy can improve overall survival (OS ...

Outpatient management of cancer-associated PE had 30-day adverse outcome rates of 1.74% for all-cause mortality, 2.71% for major bleeding, and 1.26% for recurrent VTE. Outpatient management of ...

The consensus-driven ERAS and SSC protocols established in this study provide a standardized yet adaptable framework for perioperative management of spinal metastases. The establishment of an ...

Discharge readiness associated with quality of discharge education, stoma self-efficacy, age, social support, monthly income, and gender. Insufficient discharge preparation and inadequate ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

Progression-free and overall survival do not differ for patients receiving full-dose, lowered-dose dexamethasone throughout induction. HealthDay News — For patients with newly diagnosed multiple ...

The decline in cancer incidence among men and increase among women has narrowed the male‐to-female cancer incidence rate ratio from a peak of 1.6 in 1992 to 1.1 in 2021. In people aged 50-64 years, ...

Compared with patients with undetectable ctDNA levels in this study, patients with detectable ctDNA had an increased risk of inferior EFS at day 43. Circulating tumor DNA (ctDNA) levels appear to ...

Due to a high incidence of invasive fungal infections after treatment with first- and second-generation Bruton tyrosine kinase inhibitors (BTKis), researchers are emphasizing the importance of ...

Survey results add to evidence showing that more than half of US patients with mCSPC are still receiving androgen deprivation therapy (ADT) alone or ADT with a nonsteroidal antiandrogen.